AZN.L : Summary for ASTRAZENECA PLC ORD SHS $0.25 - Yahoo Finance

U.S. Markets close in 1 hr 5 mins

AstraZeneca PLC (AZN.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
4,556.00-6.00 (-0.13%)
At close: 5:11PM GMT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close4,562.00
Bid4,490.00 x 6100
Ask4,630.00 x 13000
Day's Range4,495.00 - 4,612.77
52 Week Range3,680.00 - 5,505.00
Avg. Volume3,030,529
Market Cap57.65B
PE Ratio (TTM)16.51
Earnings DateN/A
Dividend & Yield2.80 (4.97%)
Ex-Dividend DateN/A
1y Target EstN/A
  • Benzinga7 hours ago

    Analyst: Buy AstraZeneca On The Turnaround Story

    Following AstraZeneca plc (ADR) (NYSE: AZN )’s strong start to 2017, including a positive data report for breast cancer treatment Lynparza, investors await a barrage of news highlighting significant findings ...

  • American City Business Journalsyesterday

    $250M deal: AstraZeneca sells rights to cancer therapy

    AstraZeneca entered into an agreement to sell the rights to a cancer drug in the United States and Canada to TerSera Therapeutics for an upfront payment of $250. The deal could also net AstraZeneca up to $70 million in sales-related income if revenue milestones are met, along with recurring quarterly sales-based payments that are set at a mid-teen percent of product sales. TerSera Therapeutics, which has offices in Iowa and Illinois, acquired the rights to Zoladex, an injectable drug used to treat prostate cancer, breast cancer and certain benign gynaecological disorders.

  • AstraZeneca Could Give Pfizer, Tesaro Leg Up In Breast Cancer: Leerink
    Investor's Business Daily5 days ago

    AstraZeneca Could Give Pfizer, Tesaro Leg Up In Breast Cancer: Leerink

    Pfizer and Tesaro could follow AstraZeneca which, early Friday, unveiled strong results from a trial of Lynparza in breast cancer.